The treatment of inflammatory arthritis has been revolutionized in the past decade by the introduction of targeted biologic therapies. They are genetically engineered monoclonal or fusion proteins that could interfere with the biological activity of cytokines or inhibit T cell co-stimulation or could deplete B cell [1]. …
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.